Liraglutide Injection
Product Images NDC 71288-563

Product Visual Gallery

This gallery contains 28 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 71288-563). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel – Liraglutide Injection 18 mg Per 3 mL 2-pack Carton (Lira Carton 2pack)

Packaging label for Liraglutide Injection 18 mg per 3 mL (6 mg per mL) by Meitheal Pharmaceuticals Inc. The label indicates it is a subcutaneous injection for single-patient use only. The package contains 2 pre-filled pens of 3 mL each. Storage instructions include refrigeration and not to freeze, with disposal 30 days after first use. It also notes that pen needles are not included.*

FDA Label Image

Principal Display Panel – Liraglutide Injection 18 mg Per 3 mL 3-pack Carton (Lira Carton 3pack V2)

The packaging label for Liraglutide Injection 18 mg per 3 mL (6 mg per mL) by Meitheal Pharmaceuticals Inc. The box is light blue and contains 3 pre-filled pens for subcutaneous injection. It is labeled for single-patient use only and includes information about dosage strengths and storage instructions, including refrigeration requirements. The NDC is 71288-563-84.*

FDA Label Image

Structural Formula (Lira Fig 1)

An illustration of the liraglutide molecule showing its amino acid sequence arranged in a chain with labeled residues including His, Ala, Glu, Gly, Thr, Phe, Ser, Asp, Val and others. A C-16 fatty acid (palmitoyl) is attached at a specified Glu residue, and there is a highlighted Arg residue connected to Gly and Lys, indicating structural features of the peptide molecule.*

FDA Label Image

Figure 2 (Lira Fig 2)

A line graph depicting ISR (pmol/kg/min) as a function of plasma glucose (mg/dL) concentrations comparing Liraglutide and Placebo. The graph uses a maroon diamond line for Liraglutide and a gray triangle line for Placebo, showing generally higher ISR values across increasing glucose levels for Liraglutide.*

FDA Label Image

Figure 3 (Lira Fig 3)

A line graph comparing mean HbA1c percentage over 52 weeks for three treatments: Glimepiride, Liraglutide 1.2 mg, and Liraglutide 1.8 mg. The x-axis represents time in weeks, and the y-axis shows mean HbA1c percentage. Liraglutide doses show a greater reduction in HbA1c compared to Glimepiride over time.*

FDA Label Image

Figure 4 (Lira Fig 4)

This line graph compares mean HbA1c (%) levels over 26 weeks among three treatments: liraglutide 1.2 mg, liraglutide 1.8 mg, and sitagliptin 100 mg. Both liraglutide doses show a more marked decrease in HbA1c compared with sitagliptin, with data points at baseline, 12, 18, and 26 weeks. Statistical significance is indicated for liraglutide versus sitagliptin.*

FDA Label Image

Flow Check Symbol (Lira Flow Check)

Liraglutide 6 mg/mL injectable solution in a single-dose cartridge. The label shows the product name and strength clearly, with dosage form as injection for subcutaneous use. The labeler is Meitheal Pharmaceuticals Inc. The cartridge is transparent with black printed text.*

FDA Label Image

Figure A (Lira Ifu A)

An instructional illustration showing hands preparing or handling a subcutaneous injection pen, specifically indicating removal or placement of the pen cap as part of the Liraglutide injection administration process.*

FDA Label Image

Figure B (Lira Ifu B)

Illustration showing a close-up of a hand holding a liraglutide injection pen with a finger peeling back or removing a protective cap or seal from the pen's needle area, indicating a step in preparing the pen for subcutaneous injection.*

FDA Label Image

Figure C (Lira Ifu C)

An instructional illustration showing the process of attaching or removing a needle from a subcutaneous injection pen device. A hand is holding the needle cap while aligning it with the pen's threaded tip, indicated by a directional arrow.*

FDA Label Image

Figure D (Lira Ifu D)

Instructional illustration showing the proper technique for administering a subcutaneous injection using a prefilled liraglutide injection pen. The image depicts a hand holding the injection pen with the needle approaching the skin, focusing on correct needle insertion angle and position.*

FDA Label Image

Figure E (Lira Ifu E)

An instructional diagram showing hands holding a liraglutide injection pen. The image highlights the step to check for the flow check symbol, indicating proper medication flow before administration. A close-up inset shows the symbol to confirm flow check selection.*

FDA Label Image

Figure F (Lira Ifu F)

An illustration showing a close-up of a hand holding a pen-like injector device with a needle tip, accompanied by motion lines, indicating shaking or vibration of the injection pen.*

FDA Label Image

Figure G (Lira Ifu G)

An instructional illustration showing a hand holding a liraglutide injection pen. The image depicts an upward arrow indicating the action of pulling or removing a part at the bottom of the pen. There is a close-up inset highlighting the pen's tip or cap mechanism and a dosage window displaying a zero."*

FDA Label Image

Figure H (Lira Ifu H)

An instructional illustration showing hands removing a pen cap from a subcutaneous injection pen device, indicating the first step in preparing the injection. The image includes a directional arrow emphasizing the cap removal.*

FDA Label Image

Figure I (Lira Ifu I)

An instructional diagram showing a close-up of a hand pulling a protective cap off the needle end of a subcutaneous injection pen device, indicating a preparation step for injecting liraglutide injection.*

FDA Label Image

Figure J (Lira Ifu J)

An instructional illustration showing a hand removing or attaching a pen needle to a Liraglutide injection pen. The image highlights proper handling for preparing the subcutaneous injection pen device for use.*

FDA Label Image

Figure K (Lira Ifu K)

An instructional illustration showing a close-up of a hand pressing a medical pen injector tip against a finger, demonstrating the injection process, likely for liraglutide 6 mg/mL subcutaneous injection by Meitheal Pharmaceuticals Inc.*

FDA Label Image

Figure L (Lira Ifu L)

An instructional diagram showing a person adjusting the dose on a liraglutide injection pen by turning a dial. Below, three labels display dose selections of 0.6 mg, 1.2 mg, and 1.8 mg, each highlighted next to the corresponding dial display, indicating dose options available on the device.*

FDA Label Image

Figure M (Lira Ifu M V2)

An anatomical illustration highlighting recommended injection sites for subcutaneous administration. The labeled areas include the upper arms, stomach, and thighs, shown on a frontal view of a male figure. The injection sites are shaded gray to indicate appropriate locations for liraglutide injection.*

FDA Label Image

Figure N (Lira Ifu N V2)

Instructional illustration showing a hand holding a Liraglutide injection pen. The thumb is pressing down on the top of the pen, with an arrow indicating a downward pressing motion. A small window on the pen displays the dose setting, showing 18 mg. This image is part of user guidance for dose administration.*

FDA Label Image

Liraglutide Needle (Lira Ifu Needle)

An instructional illustration showing components of a needle example: the outer needle cap, inner needle cap, needle, and protective tab, each labeled individually.*

FDA Label Image

Figure O (Lira Ifu O V2)

An instructional illustration showing a hand holding a liraglutide injection pen with an arrow indicating to press down. A stopwatch displays 6 seconds, suggesting to hold the pen in place for that duration during injection.*

FDA Label Image

Figure P (Lira Ifu P V2)

An instructional illustration showing a close-up of a liraglutide injection pen needle positioned just above the skin, with an upward-pointing arrow indicating the direction to lift or stretch the skin before injection.*

FDA Label Image

Liraglutide Injection Pen (Lira Ifu Pen)

Illustration of a Liraglutide injection pen labeled with its parts, including the pen cap, rubber stopper, cartridge tip, cartridge, cartridge scale, dose selector, pointer, dose display, dose button, and a flow check symbol depiction. The diagram provides a clear view of the pen components used for subcutaneous injection.*

FDA Label Image

Figure Q (Lira Ifu Q V2)

Illustration showing the removal of a protective cap from the tip of a liraglutide injection pen prior to subcutaneous administration. The image includes an arrow indicating the direction to pull the cap off the pen.*

FDA Label Image

Figure R (Lira Ifu R)

An instructional illustration showing two hands manipulating a syringe or injection pen. One hand holds the device while the other pulls a cap or cover off, indicated by a directional arrow pointing away from the device. The illustration is designed to guide proper handling or preparation of the injection device.*

FDA Label Image

Principal Display Panel – Liraglutide Injection 18 mg Per 3 mL Syringe Label (Lira Syringe V2)

Label for Liraglutide Injection 18 mg per 3 mL (6 mg per mL), a subcutaneous injection by Meitheal Pharmaceuticals Inc. The label indicates single-patient use only and refrigeration before use. The label includes the NDC 71288-563-83, storage instructions, and a barcode, with manufacturing in China.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.